2024;51:16651668
2024;51:16651668. purity and better tolerability. We observed excellent efficacy, yet side effects remained largely unchanged. Further studies are necessary to evaluate the longterm efficacy and tolerability of this new IVIg preparation. Keywords:adverse effects, autoimmune bullous dermatoses, intravenous immunoglobulins, IVIg, pemphigus vulgaris == 1. INTRODUCTION == Pemphigus vulgaris (PV) is one of the most severe conditions within the group of autoimmune bullous dermatoses (AIBDs). PV is usually caused by antibodies directed against Radicicol desmogleins (Dsg)desmosomal adhesion proteins that make sure epidermal integrity.1,2Histopathology reveals intraepidermal cleft formation, direct immunofluorescence reticular deposition of IgG, and C3c in the epidermis. Destruction of intracellular connections prospects to acantholysis, resulting in blistering formation. These blisters rupture easily, leading to erosions that can result in severe infections. When the oral mucosa is usually involved, severe malnutrition may occur.3Standard treatment involves systemic steroids administered alone or in combination with other immunosuppressants or rituximab.4 For severe cases of PV or in cases of inadequate response to standard treatment, intravenous immunoglobulin (IVIg) therapy has become a promising treatment approach.5IVIgs are antibodies (IgG) pooled from your serum of healthy blood and plasma donors that impact the innate and adaptive immune system leading to effective suppression of the dysregulated immune response. Mechanisms of action comprise reduction of tissue degradation through inhibition of Radicicol the match cascade and modulation of the cytokine, phagocyte, and dendritic cell activity. Moreover, IVIg therapy targets Rabbit polyclonal to HMGB4 circulating autoantibodies through mechanisms that reduce their halflife, neutralize them, and inhibit their production. Clinical, serological, and immunopathological remission is usually achieved through unique modulation of T and Bcell populations, leading to a toleranceassociated polarization of the immune system.6,7Concerning PV, there is growing evidence of IVIg effectivity in restoring dysfunctional immune regulation.8The recommended dosage of IVIg is 2 g/kg of body weight distributed over 2 to 5 days every 4 weeks.9A wide range of IVIg preparations is available, all demonstrating nearly identical efficacy. The developing process may differ, leading to slightly unique security and tolerability profiles.10 There is still a paucity of knowledge regarding the optimal IVIg preparation for the individual patient. Existing recommendations suggest a concise evaluation of preexisting conditions, such as chronic organ disorders or risk of thromboembolic events (e.g. sugarfree preparations for renal insufficiency).10Relevant criteria for selecting a particular IVIg need to be defined. Here, we statement on Radicicol a patient with ongoing remission of PV upon receiving longterm IVIg therapy who underwent a switch of IVIg preparation because of recurrent fatigue and headache. == 2. CASE Statement == We present the case of a 65yearold woman who first offered to our dermatology department in 2007 with recurrent painful erosions of the oral mucosa that caused difficulty in swallowing and a significant reduction in general condition. Histology and serology led to the diagnosis of PV. In the beginning, systemic therapy with mycophenolate mofetil 3 g/day and prednisolone 150 mg/day (2 mg/kg of body weight per day) was initiated, which resulted in a healing of lesions of the oral mucosa (Physique1). Although immunosuppressive therapy was gradually reduced, the patient reported hair loss, depressive mood, and palpitations. Because of multiple recurrences requiring further highdose steroid therapy, IVIg treatment (Intratect 100 g/L Biotest AG, 2 g/kg of body weight distributed over 2 days every 4 weeks) was initiated in 2010 2010, leading to improvement and stabilization of the skin lesions for several years. Despite ongoing IVIg treatment and concomitant immunosuppressive therapy with prednisolone 5 mg/day, recurrence in 2015 necessitated further escalation of treatment. A reinitiation of therapy with mycophenolate mofetil 3 g/day and prednisolone 150 mg/day led to significant improvement of the skin condition. To achieve longterm disease control, rituximab was administered additionally to ongoing IVIg, mycophenolate mofetil 3 g/day, and prednisolone 80 mg/day starting in May 2015. The patient received a total of 10 cycles of rituximab at a dosage of 375 mg/m2of body surface area per cycle over a total period of 21 weeks. Stabilization was reached and immunosuppression was gradually reduced; however, some.